본문으로 건너뛰기
부속서 II 항목 175 개정됨 20 10월 2010

Methylphenidate (INN) and its salts

Methylphenidate (INN) and its salts은(는) EU 시장에 출시되는 화장품에 사용이 금지된 물질로 부속서 II에 등재되어 있습니다.

사용금지 물질— 부속서 II, EU 규정 1223/2009
항목: 175

기록 세부 정보

화학명

Methylphenidate (INN) and its salts

규제 정보

규정

(EC) 2009/1223

이 법령이 설정한 모든 항목 보기

주요 데이터

부속서
항목 번호
175

화학적 정체 및 특성

CAS 113-45-1의 PubChem 2D 화학 구조
CAS 113-45-1PubChem CID 4158

Methylphenidate

Methyl phenyl(piperidin-2-yl)acetate is a amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group. It is a methyl ester, a member of piperidines and a beta-amino acid ester. — ChEBI

IUPAC 명칭
methyl 2-phenyl-2-piperidin-2-ylacetate
분자식
C14H19NO2
분자량
233.31 g/mol
정확한 질량
233.141578849 Da
XLogP3
0.2
위상 극성 표면적
38.3 Ų
수소 결합 공여체
1
수소 결합 수용체
3
공유결합 단위
1
정의된 입체중심
0

다른 이름

MethylphenidanPhenidylateCalocainPlimasineMethyl phenidylacetateMetilfenidatoMethylphenidatumMethyl phenidate
보고된 명칭 16개 더 보기
4311/B CibaDaytranaalpha-Phenyl-2-piperidineacetic acid methyl esterMethyl alpha-phenyl-alpha-(2-piperidyl)acetateNCI-C56280Methyl 2-phenyl-2-(piperidin-2-yl)acetate2-Piperidineacetic acid, alpha-phenyl-, methyl esterCotempla XR-ODTMethyl alpha-phenyl-alpha-2-piperidinylacetatealpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl esterMetilfenidat hydrochlorideThreo-dl-methylphenidatePrc-063Methylphenidate extended releaseRitalineRefChem:6033
외부 데이터베이스 식별자

추가 과학 데이터베이스의 근거

NIH PubChem PUG-View
식별자 정확히 일치4158

Attributed physical-property, hazard, environmental and use annotations.

  • Exposure Routes: Oral. Readily absorbed in a biphasic manner when orally administered (tablets) to children diagnosed with ADHD and to healthy adults. In children and adults males, after administration of a single oral dose of Ritalin LA and Ritalin given in two doses 4 hours apart, peak plasma concentration is reached approximately 2 hours for the first phase and 5-6 hours for the second phase. The absolute oral bioavailability of methylphenidate in children was 22±8% for d-methylphenidate and 5±3% for l-methylphenidate. These low values suggest that methylphenidate is highly metabolized presystemically. 출처: Toxin and Toxin Target Database (T3DB)
  • Signal: Warning 출처: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]; H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]; H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H341 (100%): Suspected of causing genetic defects [Warning Germ cell mutagenicity] 출처: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P203, P264, P264+P265, P270, P280, P301+P317, P302+P352, P305+P351+P338, P318, P321, P330, P332+P317, P337+P317, P362+P364, P405, and P501 (click each P-code to see the statement) 출처: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. 출처: European Chemicals Agency (ECHA)
  • Signal: Danger 출처: Hazardous Substances Data Bank (HSDB)
  • GHS Hazard Statements: H302: Harmful if swallowed [Warning Acute toxicity, oral]; H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory] 출처: Hazardous Substances Data Bank (HSDB)
  • Precautionary Statement Codes: P233, P260, P264, P270, P271, P284, P301+P317, P304+P340, P330, P342+P316, P403, and P501 (click each P-code to see the statement) 출처: Hazardous Substances Data Bank (HSDB)
  • Health Effects: Using large amounts of these drugs can result in a condition known as amphetamine psychosis -- which can result in auditory, visual and tactile hallucinations, intense paranoia, irrational thoughts and beliefs, delusions, and mental confusion. 출처: Toxin and Toxin Target Database (T3DB)
  • Toxicity Summary: IDENTIFICATION AND USE: Methylphenidate Hydrochloride is a psychostimulant used to treat different behavioral disorders. Indications: Used to treat narcolepsy and hyperkinetic states in children (as an adjunct to psychological, educational and social measures) for amphetamine, dextroamphetamine and ethylphenidate. It is misused for performance enhancement and relief of fatigue. Abuse either orally or by injection is extremely common. HUMAN EXPOSURE AND TOXICITY: Main risks include: Acute central nervous system (CNS) stimulation, cardiotoxicity causing tachycardia, arrhythmias, hypertension and cardiovascular collapse. High risk of dependency and abuse. Cardiovascular effects include: palpitation, chest pain, tachycardia, arrhythmias and hypertension; cardiovascular collapse can occur in severe poisoning. Myocardial ischemia, infarction and ventricular dysfunction are described. CNS effects include: stimulation of CNS, tremor, restlessness, agitation, insomnia, increased motor activity, headache, convulsions, coma and hyperreflexia. Stroke and cerebral vasculitis have been observed. Gastrointestinal effects include: vomiting, diarrhea and cramps. Genitourinary effects include: incre 출처: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: The first step in a medication overdose is to immediately contact a poison control center for the appropriate management steps. Doses that exceed 60 mg of the immediate-release formulation or 120 mg of the extended-release formulation can be considered toxic. If the overdosed quantity is unknown, the patient should be assessed for signs and symptoms such as tremors, hyperreflexia, convulsions, euphoria, confusion, hallucinations, delirium, flushing, and fever, in addition to the common adverse effects mentioned above. Supportive care with supplemental oxygen, intravenous fluids, and external cooling methods is the mainstay of treatment. Multiple studies have shown that benzodiazepines are an option, especially if dystonia, agitation, or convulsions are present. 출처: StatPearls
  • Toxicity Summary: Methylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Alteration of serotonergic pathways via changes in dopamine transport may result. 출처: Toxin and Toxin Target Database (T3DB)
  • Environmental Bioconcentration: An estimated BCF of 3 was calculated in fish for methylphenidate(SRC), using a log Kow of 0.20(1) and a regression-derived equation(2). According to a classification scheme(2), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC). 출처: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 1600(SRC), determined from a structure estimation method(2), indicates that methylphenidate is expected to have low mobility in soil(SRC). The pKa of methylphenidate is 8.9(3), indicating that this compound will exist partially in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization of the neutral species of methylphenidate from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 4.4X10-9 atm-cu m/mole(SRC), using a fragment constant estimation method(5). Methylphenidate is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 5.9X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2). Biodegradation data in soil were not available(SRC, 2015). 출처: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 1600(SRC), determined from a structure estimation method(2), indicates that methylphenidate is expected to adsorb to suspended solids and sediment(SRC). Volatilization of the neutral species from water surfaces is not expected(3) based upon an estimated Henry's Law constant of 4.4X10-9 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). A pKa of 8.9(5) indicates methylphenidate will exist partially in the cation form at pH values of 5 to 9 and, therefore, volatilization from water surfaces is not expected to be an important fate process(SRC). According to a classification scheme(6), an estimated BCF of 3(SRC), from its log Kow of 0.20(7) and a regression-derived equation(2), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Base-catalyzed second-order hydrolysis rate constant half-lives of 23 and 2.3 years at pH values of 7 and 8, respectively(2), suggest that hydrolysis may be a slow environmental fate process. Biodegradation data in water were not available(SRC, 2015). 출처: Hazardous Substances Data Bank (HSDB)
  • Environmental Fate: ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), methylphenidate, which has an estimated vapor pressure of 5.9X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase methylphenidate is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 1 hr(SRC), calculated from its rate constant of 1.1X10-10 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(3). Particulate-phase methylphenidate may be removed from the air by wet and dry deposition(SRC). Methylphenidate contains chromophores that absorb at wavelengths >290 nm(4) and, therefore, may be susceptible to direct photolysis by sunlight(SRC). 출처: Hazardous Substances Data Bank (HSDB)
  • Uses: Methylphenidate (DEA Code Number: 1724) is a Schedule II controlled substance. 출처: Hazardous Substances Data Bank (HSDB)
  • Uses: Schedule II Controlled Substance: (A) The drug or other substance has a high potential for abuse; (B) The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions; and (C) Abuse of the drug or other substances may lead to severe psychological or physical dependence. 출처: Hazardous Substances Data Bank (HSDB)
  • Uses: MEDICATION (VET) 출처: Hazardous Substances Data Bank (HSDB)
  • Uses: MEDICATION 출처: Hazardous Substances Data Bank (HSDB)
  • Uses: Central Nervous System Stimulants; Dopamine Uptake Inhibitors 출처: Hazardous Substances Data Bank (HSDB)
  • Uses: Use (kg) in Switzerland (2009): >250; Use (kg; approx.) in Germany (2009): >1000; Use (kg) in USA (2002): 9090; Consumption (g per capita) in Switzerland (2009): 0.032; Consumption (g per capita; approx.) in Germany (2009): 0.012; Consumption (g per capita) in the USA (2002): 0.032; Excretion rate: 0.1; Calculated removal (%): 92.1 출처: NORMAN Suspect List Exchange
  • Uses: For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. 출처: Toxin and Toxin Target Database (T3DB)

매핑 기준: Existing checksum-valid CAS to unique PubChem CID match. 가져온 시각: 2026-08-31. 출처 기록 열기

과학적 분류와 유해성 주석은 맥락을 제공할 뿐이며, 위에 표시된 시장별 규제 판단을 대체하지 않습니다.

추가 출처 적용 범위 및 일치 상태
출처결과확인됨
NIH PubChem PUG-View정확히 일치2026-08-31

기록된 불일치는 출처를 확인했다는 유용한 근거이며, 해당 물질이 다른 곳에 존재하지 않는다는 주장이 아닙니다.

체크섬이 유효한 CAS 일치를 통해 2026-09-02에 NIH PubChem에서 가져왔습니다. 화학적 특성은 이 페이지의 규제 판단을 대체하지 않습니다.

이 기록에 직접 일치하는 항목이 제한적이어서, 부속서 II의 인접 항목도 함께 표시합니다.

부속서 II 180
같은 부속서의 인접 기록

Fenozolone (INN)

CAS: 15302-16-6
EC: 239-339-6

Methylphenidate (INN) and its salts에 대한 부속서 II의 의미

Methylphenidate (INN) and its salts은(는) EU 화장품 규정 1223/2009 부속서 II에 따라 사용금지 물질로 등재되어 있으며 의도적으로 첨가해서는 안 됩니다. 제17조는 별도로, 우수화장품제조관리기준(GMP)에 따라 기술적으로 피할 수 없고 제3조의 안전 요건에 부합하는 비의도적 미량에 대해 다룹니다.

처방 개발자는 원료와 원재료를 선별하여 이 물질이 들어 있지 않은지 확인해야 합니다. 공급업체는 요청 시 부재를 확인하는 문서를 제공해야 합니다.

또한 이 페이지에는 식별자, 부속서 논리 또는 명칭 패턴이 겹치는 관련 부속서 기록 12건이 표시됩니다.

규제 준수 체크리스트

  • 이 물질이 모든 원료와 완제품 처방에 없는지 확인하세요.
  • 원료 공급업체에 부재 확인서 또는 CoA를 요청하세요.
  • 선별 결과를 제품정보파일(PIF)에 기록하세요.

자주 묻는 질문

예. Methylphenidate (INN) and its salts은(는) EU 화장품 규정 1223/2009 부속서 II에 등재되어 있으며 의도적으로 첨가하는 화장품 원료로는 사용이 금지됩니다. 제17조는 제품이 제3조에 따라 안전하게 유지되는 경우에 한해, GMP에 따라 기술적으로 피할 수 없는 비의도적 미량에 대해 좁은 예외를 둡니다.

CAS 113-45-1은(는) Chemical Abstracts Service가 Methylphenidate (INN) and its salts에 부여한 고유 숫자 식별자입니다. 화장품 규제 준수 업무에서 CAS 번호는 규제 데이터베이스, 원료 규격 및 안전성 평가 보고서 전반에서 물질을 교차 참조하는 데 사용됩니다. 같은 물질이 다른 조건이나 다른 부속서에 나타나는 경우 여러 EU 부속서 항목이 같은 CAS 번호를 공유할 수 있습니다.

이 사이트의 INCI 검사기에 전체 성분 목록(INCI)을 붙여넣어 모든 부속서 II–VI 항목과 대조하세요. 이 도구는 사용제한, 사용금지 또는 알레르겐으로 표시된 기록과 일치하는 원료를 강조 표시합니다. 완제품 처방이나 원료 선언서를 빠르게 선별하는 데 유용합니다.

부속서 II 기록 Methylphenidate (INN) and its salts의 출처 주석

이 페이지는 공개된 유럽연합 집행위원회 화장품 자료에서 가져온 Methylphenidate (INN) and its salts의 부속서 II 기록 하나를 요약하고, 가능한 경우 연결된 목록 또는 식별자 일치 항목을 추가합니다.

이 기록 페이지를 이용해 Methylphenidate (INN) and its salts의 부속서 II 조건을 검토하되, 최종 규제 판단은 현행 공식 부속서 문구 및 원본 파일로 확인하세요.

도구 및 다음 단계

처방 확인

전체 INCI 목록을 붙여넣어 Methylphenidate (INN) and its salts 및 기타 표시된 EU 부속서 기록을 한 번에 찾아보세요.

INCI 검사기

항목 비교

Methylphenidate (INN) and its salts을(를) 다른 부속서 기록과 나란히 비교하여 제한 사항, 농도 및 부속서 위치의 차이를 검토하세요.

비교

부속서 둘러보기

부속서 II의 모든 기록을 확인하고 이 부속서 내 물질 간의 규제 조건을 비교하세요.

부속서 II 열기